Long, G., Dummer, R., Ribas, A., Puzanov, I., Michielin, O., Vanderwalde, A., Andtbacka, R., Cebon, J., Fernandez, E., Malvehy, J., Olszanski, A., Gajewski, T., Kirkwood, J., Gause, C., Chen, L., Kaufman, D., Chou, J., & Hodi, F. (n.d.). 24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma. European journal of cancer, 51, S722–. http://access.bl.uk/ark:/81055/vdc_100030687872.0x00005c